ST Pharm Co.,Ltd.
Financials
Valuation Metrics
ST Pharm Co.,Ltd.'s Market Cap is ₩1.5T. At end of 2025 it was ₩2.5T. Ranked #236 of 2,405 in KR market (top 10%), #52 of 1,627 on KOSDAQ (top 3%), #23 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.51T KRW | KR#236/2,405 Sec#23/231 |
| Revenue | 386.46B KRW | KR#733/2,405 Sec#34/231 |
| Net Income | 76.84B KRW | KR#306/2,405 Sec#22/231 |
| Total Assets | 848.03B KRW | KR#529/2,405 Sec#28/231 |
| Net Assets | 629.07B KRW | KR#423/2,405 Sec#28/231 |
| Employees | 1,328 | KR#197/2,405 Sec#12/231 |
| Value | ||
| P/E | 19.67x | KR#1,197/2,405 Sec#72/231 |
| P/B | 2.40x | KR#2,060/2,405 Sec#159/231 |
| PEG | 0.14x | KR#507/2,405 Sec#29/231 |
| P/S | 3.91x | KR#2,093/2,405 Sec#135/231 |
| EV/EBITDA | 21.61x | KR#1,078/2,405 Sec#67/231 |
| FCF Yield | -2.19% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 12.21% | KR#462/2,405 Sec#32/231 |
| ROA | 9.06% | KR#340/2,405 Sec#26/231 |
| Op. Margin | 18.33% | KR#197/2,405 Sec#19/231 |
| Revenue Growth | 29.64% | KR#394/2,405 Sec#40/231 |
| Earnings Growth | 138.55% | KR#324/2,405 Sec#19/231 |
| Financial Health | ||
| Debt Ratio | 34.81% | KR#684/2,405 Sec#84/231 |
| Total Debt | 72.77B KRW | KR#847/2,405 Sec#57/231 |
| FCF | -33.08B KRW | KR#1,998/2,405 Sec#194/231 |
| Cash | 53.83B KRW | KR#705/2,405 Sec#39/231 |
| Current Ratio | 2.28x | KR#759/2,405 Sec#90/231 |
| Net Debt/EBITDA | 0.27x | KR#638/2,405 Sec#38/231 |
| Dividend | ||
| Div. Yield | 0.69% | KR#1,222/2,405 Sec#74/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -28.53% | KR#1,399/2,405 Sec#107/231 |
| 1M Return | -22.40% | KR#1,990/2,405 Sec#193/231 |
| From 52W High | -57.93% | KR#1,559/2,405 Sec#127/231 |
| 1Y MDD | -57.08% | KR#1,273/2,405 Sec#106/231 |
| Trading | ||
| Volume | 73,712 shares | KR#763/2,405 Sec#80/231 |
| Trading Value | 5.35B KRW | KR#290/2,405 Sec#23/231 |
| Foreign Own. | 12.61% | KR#392/2,405 Sec#29/231 |
| Per Share | ||
| EPS | 3,681 KRW | KR#290/2,405 Sec#19/231 |
| BPS | 30,133 KRW | KR#375/2,405 Sec#27/231 |
Company Info
ST Pharm was founded as UCHEM Co., Ltd. in 2008, then changed its name after an absorption merger with Samchully Pharmaceutical in 2010, subsequently joining the Dong-A Socio Group. Leveraging its expertise in small molecule new drugs, the company has expanded into oligonucleotide therapeutics CDMO. ST Pharm holds the world's third-largest production capacity, initiated production with the expansion of its second oligonucleotide plant in 2025, and provides a one-stop service system encompassing new drug development, CRO, and CDMO. It is headquartered in Siheung-si, Gyeonggi-do.